Gyre Therapeutics (GYRE) Total Non-Current Liabilities (2016 - 2025)
Gyre Therapeutics (GYRE) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $20.9 million as the latest value for Q4 2025.
- Quarterly Total Non-Current Liabilities fell 2.1% to $20.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.9 million through Dec 2025, down 2.1% year-over-year, with the annual reading at $20.9 million for FY2025, 2.1% down from the prior year.
- Total Non-Current Liabilities for Q4 2025 was $20.9 million at Gyre Therapeutics, up from $18.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $33.3 million in Q4 2023, with the low at $1.8 million in Q3 2023.
- Average Total Non-Current Liabilities over 4 years is $17.2 million, with a median of $18.7 million recorded in 2025.
- Peak annual rise in Total Non-Current Liabilities hit 1699.95% in 2024, while the deepest fall reached 36.01% in 2024.
- Over 4 years, Total Non-Current Liabilities stood at $12.5 million in 2022, then soared by 165.98% to $33.3 million in 2023, then crashed by 36.01% to $21.3 million in 2024, then fell by 2.1% to $20.9 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $20.9 million, $18.7 million, and $20.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.